Search results
Three Indian CDMOs ready to seize the BIOSECURE Act opportunity
BioPharma-Reporter· 4 days agoSpearheading this effort is the BIOSECURE Act, a bipartisan initiative gaining traction in Congress...
MilliporeSigma Announces Siren Biotechnology As Winner Of Its North American Advance Biotech Grant
BioresearchOnline· 7 days agoMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany,...
Moderna flu/COVID combo beats immune responses for approved shots in phase 3 after speedy season
FierceBiotech· 10 hours agoModerna’s combo flu and COVID-19 vaccine zipped through a late-stage trial this winter, and the...
These Biotech Stocks Hit New Highs, Did You Reap The Rewards?
RTT News· 3 days agoProtagonist is a clinical-stage biopharmaceutical company with multiple assets having billion-dollar market potential. The company has a worldwide license and collaboration ...
Regulatory Expert Appointed to Lead West Coast US Client Engagement for G&L Healthcare Advisors
Digital Journal· 7 days agoRichard has a strong track record of helping over 50 companies secure regulatory approval. Richard brings a unique and compelling combination of technical expertise
India’s Modi Wins Again, Lawyers Position Practices for Growth | Law.com International
Law.com· 5 days agoAlthough the election was closer than expected, Narendra Modi has once again secured the position of...
ICON (ICRL) Gains From Strategic Acquisitions, Innovation
Zacks via Yahoo Finance· 3 days agoIn addition to its focused efforts within the biotech segment, ICON continues to drive forward its...
70-year-old King of Prussia company acquired - Philadelphia Business Journal
The Business Journals· 7 days agoIt serves a range of end markets including industrial gas, federal and defense, engineering and...
Here’s Why Jim Cramer Says You Should Not Buy Bristol-Myers Squibb Co (NYSE:BMY)
Insider Monkey via Yahoo Finance· 5 days agoWe recently published the list of 11 stocks Jim Cramer is bearish on. Bristol-Myers Squibb Co...
Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance?
Motley Fool via Yahoo Finance· 3 days agoAnd Zepbound is on its way to becoming a blockbuster drug, too, delivering more than $500 million in...